Source link : https://www.newshealth.biz/health-news/drug-combo-for-common-neuroendocrine-tumor-a-new-standard/
Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors compared with everolimus alone. This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors, said Susumu Hijioka, MD, from […]
Author : News Health
Publish date : 2025-01-27 09:17:32
Copyright for syndicated content belongs to the linked Source.
Categories